Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmasyntez
While the total number of clinical trials given the go-ahead in Russia saw only a very small decline last year, average timelines for study approvals increased significantly because of factors linked to COVID-19.
With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.